|
The CryoPen Newsletter
The CryoPen®~ Now For Use in Women's Health and
Treatment of Genital Warts
March, 2013 - Vol 1, Issue 2
|
|
|
|
VISIT US AT THE NCCHC SPRING CONFERENCE
APRIL 20-23, 2013
|
SPRING CONFERENCE
ON CORRECTIONAL
HEALTH CARE
BOOTH # 508
For more information visit their website at: www.ncchc.org
|
| STATISTICS- HPV |
|
According to the Centers for Disease Control (CDC) there are more than 40 types of HPV that can infect the genital areas of both males and females.
HPV is passed through genital contact, most often during vaginal and anal sex.
Approximately 79 million Americans are currently infected with HPV.
About 14 million people become newly infected each year.
About 12,000 women in the U.S. get cervical cancer each year.
Each year in the U.S., HPV is thought to cause an estimated
- 2,100 vulvar cancers
- 500 vaginal cancers
- 600 penile cancers
- 2,800 anal cancers in women
- 1,500 anal cancers in men
According to the CDC fact sheet about 1% of sexually active men in the U.S. have genital warts at any one time.
Currently, there is no HPV test recommended for men. The only approved HPV tests on the market are for screening women for cervical cancer.
For more information visit the CDC's website at:
http://www.cdc.gov
|
CODING CORNER- DYSPLASIA OF THE CERVIX
|
|
Most Non-Malignant issues of the Cervix are caused by the Papilloma Virus (HPV).
If coding for Dysplasia of the Cervix-unspecified, use ICD-9-CM (622.10)
The 2013, ICD-10-CM for code 622.10 states the following: Irregularity or alteration from normal cervical tissue. The spatial orientation of the cervical cells is often aberrant due to the lack of an organized growth process. This medical code can be used to specify a diagnosis on a reimbursement claim.
If converting from ICD-9-CM to ICD-10-CM, the new code will be N87.9. The description is: Dysplasia of cervix uteri, unspecified.
If the patient has a history of Cervical Dysplasia, you will use code ICD-9-CM (V13.22)
converted to ICD-10-CM (Z87.410). The description is: Personal history of cervical dysplasia.
For more assistance with diagnosis codes and/or converting your existing ICD-9-CM codes to ICD-10-CM, visit the following website: www.icd9data.com
This information is provided to assist you in determining possible codes for procedures performed and are presented as examples only. Please check your current coding book for a more extensive list and for any coding changes.
Please visit: www.cms.gov/apps/physician-fee-schedule to obtain your state's reimbursement fees.
|
|
|
THE CryoPen® ~ THE NEWEST TECHNOLOGY FOR THE TREATMENT OF GENITAL WARTS.
|
|
Genital Warts are caused by the Human Papilloma Virus (HPV).
The Centers for Disease Control and Prevention estimate that about 360,000 persons in the U.S. get genital warts each year.
|
GENITAL WARTS
|
 |
|
GENITAL WARTS
Found on shaft of penis, vagina, vulva, cervix, and around anus.
|
Condylomata, (Genital Warts) are caused by HPV and its visual manifestation is dependent on many factors such as the individual's immune system, treatment history, and smoking history. Even with visual resolution of genital lesions, there is no guarantee that HPV is gone or simply dormant. No oral treatments for Condylomata exist. Available treatments are topical chemicals or physical destructive methods. Like all wart treatments, no one treatment methodology exists that will eliminate the warts 100% of the time. Some topical chemicals cannot be used in pregnancy and some may cause fungal infections. Destructive methods that vaporize (laser or cautery) viral particles may be a risk to health care workers. Cryosurgery is a destructive method not requiring local anesthesia. It is also a destructive method for condylomata removal which produces less scarring than other treatment modalities.
TREATMENT USING THE CryoPen®
Condylomata may have smooth or irregular surfaces. If there are any irregularities of the surface, a topical water based material should be applied. A standard ultrasound gel, water based K-Y type lubricant, or a water based moisturizer should suffice. A very thin coat of the water based material will increase thermal conduction to the Condylomata when applied.
Use a CryoPen® tip that will completely cover the warty lesion. Place a cold CryoPen® core into the tip after checking for proper temperature with the Temperature Indicator. Apply the cold CryoPen® tip to the lesion, making contact and time the treatment. Treatment times should last 20 to 45 seconds. Large, raised lesions should have longer treatment times; whereas smaller, superficial lesions should have shorter treatment times. Instructions for post-treatment care should be given. Lesions along clothing lines may benefit from a small bandage covering to prevent rupture of any potential blistering that may occur. Like all cryo-lesions, no other special treatment is necessary unless a blister that formed ruptures prematurely, allowing for potential infection. Antibiotic topical ointment may be used.
The CryoPen® uses no cryogenic gasses or liquids and it offers the most advanced state-of-the-art cooling technology.
 |
|
No Tethers or Tanks to Restrict Mobility
|
|
THE CryoPen® ~ CERVICAL CRYOSURGERY WITHOUT LIQUID NITROGEN OR NITROUS OXIDE
|
 |
|
For use with the CryoPen® Base unit.
|
The CryoPen® allows medical professionals to provide cervical cryosurgery without the traditional use of dangerous cryogenic gasses or liquids.
CryoPen's GYN accessory kit delivers treatment at -105 degree Celsius and is intended for use in the ablation of Cervical Intraepithelial Neoplasia (CIN), grades 1 and 2.
"In addition to the ease of treatments that don't rely on dangerous gasses, the CryoPen® System can make a difference in areas that are underserved by gas delivery including developing countries," says Dr. Michael Haas, President of CryoPen, Inc. "Many countries have barred the use of nitrous oxide because of its ozone depleting and greenhouse attributes".
Greater access to cryotherapy treatments could mean fewer deaths from cervical cancer. CryoPen's GYN System offers the ability to provide cervical cryosurgery treatments in underdeveloped nations, potentially saving tens of thousands of lives where incidence and mortality ratios due to cervical cancer are high.
Cervical cancer is preventable if detected and treated early on. CryoPen's Cryosurgical GYN System is poised to become the leading technology in the fight against cervical cancer.
The GYN accessory kit for use with the CryoPen® unit offers accurate pen-point precision and a consistent freeze temperature, which can be monitored using the CryoPen® Temperature Indicator. The CryoPen® makes cryosurgery simple, safe, and effective.
|
| CRYOPEN IN THE NEWS |
- Visit us at the NCCHC Spring Conference April 20-23, 2013 in Denver, CO
- CryoPen Celebrates 10th Anniversary of Original FDA Clearance
- CryoPen, Inc Featured in Startech Foundation Annual Report
- Medical Device Maker CryoPen Inc. Selected to present at WBT Innovative Marketplace in San Diego
|
|
|
|
CryoPen FAQ's
|
|
Question:
Why is cryosurgery a preferred treatment method for CIN 1 and CIN 2?
Answer:
Studies show that cervical length in the second trimester to be the primary predictor of preterm delivery. Procedures which excise a portion of the distal cervix are associated with an increased risk of preterm delivery. Excisional modalities can include cold knife conization, LEEP, and LLETZ. They can remove a portion of the distal cervical canal during the procedure. Cryosurgery has not been shown to cause any permanent damage to the cervical canal.
For more information on the CryoPen, please visit our website at: www.cryopen.com or call us at
1-888-246-3928.
|
|
 2013 Copyright . All Rights Reserved. MM1304-V2 |
|
|
|
|
